Form 8-K - Current report:
SEC Accession No. 0001437749-23-022524
Filing Date
2023-08-08
Accepted
2023-08-08 16:23:49
Documents
13
Period of Report
2023-08-03
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K navb20230808_8k.htm   iXBRL 8-K 27097
  Complete submission text file 0001437749-23-022524.txt   173612

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA navb-20230803.xsd EX-101.SCH 3848
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE navb-20230803_def.xml EX-101.DEF 13379
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE navb-20230803_lab.xml EX-101.LAB 17543
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE navb-20230803_pre.xml EX-101.PRE 13356
7 EXTRACTED XBRL INSTANCE DOCUMENT navb20230808_8k_htm.xml XML 4272
Mailing Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017
Business Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000810509 (see all company filings)

EIN.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35076 | Film No.: 231151761
SIC: 2835 In Vitro & In Vivo Diagnostic Substances